March 16, 2025 - 08:54

Elon Musk and Sam Altman have come to a significant agreement regarding their ongoing dispute over OpenAI's transition to a for-profit model. The two influential figures in the tech industry have decided to expedite a trial that will address the contentious issues surrounding this shift in the company's structure.
This decision marks a pivotal moment in their relationship, as both Musk and Altman have been vocal about their differing perspectives on the future direction of OpenAI. The trial will delve into the implications of this transition, examining how it affects the organization's mission to ensure artificial intelligence benefits all of humanity.
As the trial approaches, industry observers are keenly watching how the outcome may influence the broader landscape of AI development and regulation. This agreement to expedite the proceedings reflects the urgency both parties feel in resolving their differences, underscoring the high stakes involved in the evolution of artificial intelligence technology.
July 10, 2026 - 04:47
Baker Hughes CEO: Continued business tailwinds with the need for power generation and LNGLorenzo Simonelli, the chief executive of Baker Hughes, appeared on `Power Lunch` to discuss the company`s outlook, pointing to sustained business tailwinds fueled by the growing need for power...
July 9, 2026 - 04:31
The Software Business Model Is Running Out of Time—and So Are Software StocksThe era of easy money for traditional software companies is coming to an end, and Wall Street is starting to panic. According to analysts at Stifel, the old ways of selling software-think long-term...
July 8, 2026 - 00:07
George E. Johnson Sr., founder of a pioneering Black hair care business, dies at 99George E. Johnson Sr., the visionary entrepreneur who built a multimillion dollar hair care empire and broke racial barriers on Wall Street, has died. He was 99. His family confirmed he passed away...
July 7, 2026 - 02:47
Medtronic recalls heart valve delivery system due to safety riskMedtronic has announced a recall for a specific heart valve delivery system, citing a safety risk that could affect patients. The recall involves the company`s Evolut FX and Evolut PRO+ delivery...